The latest price situation of Teclistamab-cqyv in 2025

Teritusumab (Teclistamab-cqyv) is a bispecific monoclonal antibody targeting B cells. It is mainly used to treat multiple myeloma (MM) and other hematological malignancies. The drug simultaneously binds to CD19 on the surface of B cells and CD3 on the surface of T cells, thereby activating the immune response mediated by T cells and achieving the effect of eliminating tumor cells. In recent years, with the rapid development of targeted therapy and immunotherapy, teritusumab, as an innovative drug, has shown good clinical efficacy and safety, and has attracted widespread attention from doctors and patients.

In China, teritusumab has received marketing approval and has begun external sales. However, due to its short time on the market, relevant information such as selling price and medical insurance reimbursement is still unclear. Based on the current situation, the selling price of terituximab abroad can provide us with a reference. Taking the European version of Teritusumab as an example, each box of 30mg/3ml is priced at more than RMB 10,000, while each box of 153mg/1.7ml (90mg/ml) is priced at more than RMB 50,000 (the price may fluctuate due to exchange rates). In addition, there are no generic drugs of teritusumab on the market at home or abroad. .

The application scenarios of teritusumab are mainly focused on the treatment of patients with multiple myeloma. Multiple myeloma is an aggressive and difficult-to-treat blood cancer, so finding effective treatments is particularly important. The dual-targeting mechanism of teritusumab gives it unique advantages in treatment and can effectively improve patients' survival rate and quality of life. Clinical trial data show that teritusumab has a high response rate in patients with multiple myeloma, and the drug is well tolerated and the side effects are relatively controllable.

Reference materials:https://www.tecvayli.com/